• Aprea is like a startup Amgen or Gilead Sciences, singularly focused on developing innovative cancer drugs in clinical trials.
• Think of Aprea as the highly specialized cancer research division of a company like Pfizer or Merck, but operating independently as a clinical-stage biotech.

Aprea Therapeutics (APRE) Major Products:

• APR-246: A small molecule p53 reactivator in late-stage clinical development for hematologic malignancies and various solid tumors.
• APR-548: A p53 reactivator in Phase I clinical trials for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Aprea Therapeutics (APRE) is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. As described, their lead product candidates, APR-246 and APR-548, are in various phases of clinical trials (late-stage, Phase I, Phase I/II).

Given that Aprea Therapeutics is a clinical-stage company, its products have not yet been approved for commercial sale and are not generating revenue from product sales. Therefore, the company does not currently have major customers, either other companies or individual consumers, in the traditional sense.

The key risks for Aprea Therapeutics (APRE) include:

1. Financial Instability and Going Concern Risk: Aprea Therapeutics has explicitly stated a "going concern" risk, with its cash reserves projected to fund operations for a limited period, necessitating continuous efforts to secure additional financing. The company has a history of decreasing cash reserves and recurring net losses. Furthermore, it has engaged in multiple private placements, leading to shareholder dilution as it raises capital.
2. Significant Clinical Development and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Aprea Therapeutics faces the inherent high risk of failure in clinical trials, where a substantial percentage of drug candidates do not advance through all stages. The company has a documented history of regulatory challenges, including FDA safety and clinical holds on its former lead drug, eprenetapopt (APR-246), which led to a Phase 3 trial failing to meet its primary endpoint. While the company has new lead programs like APR-1051 and ATRN-119, these are in early clinical stages, and their success, timing, and cost are subject to considerable uncertainty.
3. High Dependence on a Limited Product Pipeline: Aprea Therapeutics' future success and valuation are heavily reliant on the successful development, regulatory approval, and eventual commercialization of a very limited number of product candidates. Recent reports indicate an increased focus on a single drug, APR-1051, in its valuation model. This concentration risk amplifies the impact of any setbacks or failures in its clinical programs.

The primary clear emerging threat to Aprea Therapeutics is the potential for competitor biopharmaceutical companies to develop and commercialize alternative or superior treatments for the same indications that Aprea's lead candidates, APR-246 and APR-548, are targeting, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As Aprea's products are still in clinical development, the continuous emergence of new therapies, whether through different mechanisms of action or superior efficacy/safety profiles, from other companies poses a direct and significant risk to the future market penetration and commercial viability of Aprea's product pipeline.

Aprea Therapeutics, Inc. (APRE), a clinical-stage biopharmaceutical company focused on reactivating mutant p53 tumor suppressor protein, has primary product candidates, APR-246 (eprenetapopt) and APR-548, targeting various hematologic malignancies and solid tumors.

The addressable markets for Aprea Therapeutics' main products and services are as follows:

Myelodysplastic Syndromes (MDS)

The global myelodysplastic syndrome (MDS) drugs market was valued at approximately USD 2.8 billion in 2023 and is projected to reach USD 5.5 billion by 2032, growing at an 8% Compound Annual Growth Rate (CAGR) from 2024 to 2032. Another estimate for the global MDS drugs market indicates a size of USD 4.55 billion in 2024, with a projection to reach USD 11.17 billion by 2034, expanding at a CAGR of 9.4% from 2025 to 2034. In the United States, the MDS market size was estimated to be nearly USD 2 billion in 2023.

Acute Myeloid Leukemia (AML)

The global acute myeloid leukemia (AML) treatment market was valued at approximately USD 2.82 billion in 2025. This market is projected to reach around USD 10.64 billion by 2035, demonstrating a CAGR of 10.64% between 2026 and 2035. Another projection estimates the global AML treatment market to grow from USD 2.6 billion in 2025 to USD 5.1 billion by 2032, at a CAGR of 10.0% during the forecast period. North America is a significant region in this market, holding approximately 38% of the global market share in 2025.

TP53 Mutant Chronic Lymphocytic Leukemia (CLL)

While specific market sizes for TP53 mutant chronic lymphocytic leukemia are not readily available as a standalone market, the broader global chronic lymphocytic leukemia (CLL) therapeutics market offers insight. This market was valued at USD 5.42 billion in 2025 and is projected to grow to USD 7.91 billion by 2031, with a CAGR of 6.51% from 2026 to 2031. Another estimate values the global CLL market at USD 5.4 billion in 2025, projected to reach USD 10.3 billion by 2035, growing at a CAGR of 6.6%. The United States CLL market is estimated to be USD 1.9 billion in 2025, anticipated to reach USD 3.2 billion by 2035. The identification of TP53 mutations in CLL patients enables the development of targeted therapies.

Cellular Tumor Antigen p53 Market (Targeting p53 Cancer Therapies)

A broader market directly relevant to Aprea's p53 reactivator products is the global Cellular Tumor Antigen p53 market, which is projected to reach an estimated USD 5.8 billion by 2025. This market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.8% from 2025 to 2033. Another report valued the global Targeting p53 Cancer Therapies market at USD 1.45 billion in 2024, with a projection to grow from USD 1.65 billion in 2025 to USD 3.21 billion by 2032, exhibiting a CAGR of 10.2%. North America is the dominant region in this market, accounting for over 45% of global revenue in 2024.

Solid Tumors (Gastric, Bladder, and Non-Small Cell Lung Cancers with TP53 Mutation)

Aprea Therapeutics has APR-246 in Phase I/II clinical trials for relapsed/refractory gastric, bladder, and non-small cell lung cancers. Specific addressable market sizes for these solid tumors, specifically those with TP53 mutations, are not identifiable as distinct markets within the provided information.

Expected Drivers of Future Revenue Growth for Aprea Therapeutics (APRE)

Over the next 2-3 years, Aprea Therapeutics' future revenue growth is anticipated to be driven by the following key factors:

1. Advancement and Potential Commercialization of APR-1051: Aprea Therapeutics' lead program, APR-1051, a next-generation WEE1 inhibitor, is in Phase 1 clinical development for advanced solid tumors and has shown promising anti-tumor activity and a favorable safety profile. Successful completion of dose escalation, continued positive efficacy and safety data from ongoing and future trials, and subsequent progression towards regulatory approval and commercial launch would be a significant revenue driver.
2. Development of APR-1051 in New Indications and Patient Populations: The company is strategically amending its clinical protocol for APR-1051 to include more patients with HPV-positive tumors, an area identified as having substantial unmet medical need. Expanding the clinical development and potential market for APR-1051 into additional solid tumor types, such as ovarian, endometrial, colorectal, prostate, and breast cancers, also presents a future revenue growth opportunity.
3. Advancement of ATRN-119 in Combination Therapies: Aprea's ATR inhibitor, ATRN-119, has reached its recommended Phase 2 dose, and the company is now focusing on evaluating it in combination strategies with other cancer treatments. Preclinical findings suggest that ATR inhibition may enhance anti-tumor immune responses when combined with radiation and immunotherapy. Successful development and clinical trials of these combination therapies could broaden ATRN-119's therapeutic potential and market.
4. Strategic Collaborations and Partnerships: Aprea's existing translational research collaboration with MD Anderson Cancer Center, particularly in exploring APR-1051's activity in HPV-positive tumor types and its synergy with anti-PD-1 therapy, highlights the potential for future strategic collaborations. Such partnerships could accelerate clinical development, market access, and ultimately contribute to revenue growth.
5. Strengthening and Leveraging Intellectual Property: Aprea Therapeutics has actively expanded and strengthened its global patent portfolio for both its WEE1 (APR-1051) and ATR (ATRN-119) inhibitor programs. This robust intellectual property protection, with patents potentially extending into the 2040s, is crucial for long-term value creation, potential licensing agreements, and protecting future commercialized products from competition.

Share Issuance

• Aprea Therapeutics secured approximately $5.6 million in gross proceeds from a private placement in January 2026, selling 6,288,857 shares of common stock (or pre-funded warrants) and warrants to purchase an equal number of shares at a combined effective offering price of $0.89 per unit.
• In December 2025, the company raised approximately $3.1 million through a private placement, issuing 2,623,023 shares of common stock (or pre-funded warrants) and accompanying warrants at a combined offering price of $1.165 per share. This financing was expected to extend the company's cash runway into the first quarter of 2027.
• In March 2024, Aprea announced a securities purchase agreement with investors to raise up to $34.0 million in gross proceeds, including an initial upfront funding of $16.0 million and potential additional funding of up to $18.0 million from warrant exercises.

Inbound Investments

• The company received approximately $5.6 million from a January 2026 private placement with new and existing healthcare-focused institutional investors and certain insiders.
• A December 2025 private placement brought in approximately $3.1 million from new and existing healthcare-focused investors and company insiders.
• In March 2024, Aprea secured an initial $16.0 million (part of a potential $34.0 million) through a private placement from new and existing healthcare institutional investors and certain company insiders.

Capital Expenditures

• Proceeds from financing activities, such as the January 2026 private placement, are intended for general corporate purposes and research and development (R&D) expenses. The January 2026 funds were specifically targeted to "proactively backfill patients at key dose levels in our ongoing ACESOT-1 dose-escalation study evaluating APR-1051, our WEE1 kinase inhibitor."
• The capital raised in March 2024 was allocated for general working capital and to fund the Phase 1 ACESOT-1051 clinical trial, as well as continued patient enrollment in the ABOYA-119 clinical trial.
• Research and Development expenses were $1.6 million for the first quarter of 2024, $1.9 million for the second quarter of 2025, and $1.6 million for the third quarter of 2025. The company projected its cash and cash equivalents as of September 30, 2025, to be sufficient for operating expenses and capital expenditure requirements into the fourth quarter of 2026.